Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression

Obesity Research

Volumn 11, Issue 4, 2003, Pages 525-531

  Bulló, Monica ^a   García Lorda, Pilar ^a   Megias, Isabel ^a   Salas Salvadó, Jordi ^a,b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Albumin; C reactive protein; IL 6; Leptin; TNF system

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; LEUKOCYTE ANTIGEN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD; BODY COMPOSITION; BODY MASS; CHEMISTRY; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LEUKOCYTE COUNT; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADIPOSE TISSUE; ADULT; ANTIGENS, CD; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LEPTIN; LEUKOCYTE COUNT; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142248881     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2003.74     Document Type: Article

References (47)

1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-24.
2. Manson J. Risk modification in the diabetic patient. In: Manson J, Ridker P, Gaziano J, Hennekens C, eds. Prevention of Myocardial Infarction. New York: Oxford University Press; 1996, pp. 241-73.
3. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-3.
4. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease. JAMA. 1998;279:1477-82.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.
6. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131-5.
7. Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res. 2000;8:673-5.
8. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9:414-7.
9. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vasc Biol. 1999;19:972-8.
10. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95:2111-9.
11. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196-200.
12. Caro JF, Sinha MK, Kolaczybski JW, Zhang PL, Considine RE. Leptin: the tale of an obesity gene. Diabetes. 1996;45:1455-62.
13. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286-92.
14. Yudkin JS, Kumari M, Humphries S, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000;148:209-14.
15. Stephens JM, Pekala PH. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha: regulation is coordinate and independent of protein synthesis. J Biol Chem. 1992;267:13580-584.
16. Banks RE, Forbes MA, Storr M, et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol. 1995;102:217-23.
17. Papanicolau DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127-37.
18. Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 1999;99:2221-2.
19. Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem. 1987;262:8390-4.
20. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 1992;52:4113-6.
21. Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes. 1997;46:313-6.
22. Fehmann HC, Peiser C, Bode HP, et al. Leptin: a potent inhibitor of insulin secretion. Peptides. 1997;18:1267-73.
23. Bulló M, García-Lorda P, Peinado-Onsurbe J, et al. TNF expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis. Int J Obes. 2002;26:652-8.
24. Valtueña S, Blanch S, Barenys M, Sola R, Salas-Salvadó J. Changes in body composition and resting energy expenditure after rapid weight loss: is there an energy metabolism adaptation in obese patients?. Int J Obes. 1995;19:119-25.
25. Segal KR, Van Loan M, Fitgerald PI, Hodgdon JA, Van Itallie TB. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study. Am J Nutr. 1988;47:7-14.
26. Corica F, Allegra A, Corsonello A, et al. Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects. Int J Obes. 1999;23:355-60.
27. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1998;21: S5-19.
28. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847-50.
29. Pradham AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-34.
30. Pasulka P, Bistrian BR, Blackburn GL. Obesity and erythrocyte sedimentation rates. Ann Intern Med. 1995;103:304.
31. Schmidt MI, Duncan BB, Sharret AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353:1649-52.
32. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1999;22:767-72.
33. Bastard JP, Jardel C, Blondy P, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000;85:3338-42.
34. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564-9.
35. Laimer M, Ebenbichler CF, Kaser S, et al. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord. 2002;26:659-62.
36. Zhang Y, Lin JX, Yip YK, Vilcek J. Stimulation of interleukin-6 in mRNA levels by tumor necrosis factor and interleukin-1. Ann N Y Acad Sci. 1989;557:548-9.
37. Bemelmans MHA, Van Tis LJH, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol. 1996;16:1-11.
38. Bulló M, García-Lorda P, Salas-Salvadó J. Serum sTNF receptors and leptin levels in normal weight and obese women: effect of adiposity and diabetes. Eur J Endocrinol. 2002;146:325-31.
39. Loffreda A, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune response. FASEB J. 1998;12:57-65.
40. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation and hematopoiesis. J Leukoc Biol 2000;68:437-46.
41. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest. 1997;100:2777-82.
42. Fawcett RL, Waechter AS, Williams LB, et al. Tumor necrosis factor-alpha inhibits leptin production in subcutaneous and omental adipocytes from morbidly obese humans. J Clin Endocrinol Metab. 2000;85:530-5.
43. Pickup JC, Chusney D, Mattock MB. The innate immune response and type 2 diabetes: evidence that leptin is associated with a stress-related (acute-phase) reaction. Clin Endocrinol. 2000;52:107-12.
44. Kern PA, Ranghanathan S, Li Chungling, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2002;280:E745-51.
45. Dann MS, Hsu CJ, Lange MP, Jefferson LS. Effects of tumor necrosis factor-alpha on glucose and albumin production in primary cultures of rat hepatocytes. Metabolism. 1994;43:476-80.
46. Dich J, Gluud CN. Effect of insulin on albumin production and incorporation of 14C-leucine into proteins in isolated parenchymal liver cells from normal rats. Acta Physiol Scand. 1975;4:236-43.
47. Grieninger G, Plant PW, Laing TJ, et al. Hormonal regulation of fibrinogen synthesis in cultured hepatocytes. Ann N Y Acad Sci. 1983;408:469-89.